Condition
Impaired Hypoglycemic Awareness clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Impaired Hypoglycemic Awareness clinical trials that are recruiting, at sites in 11 countries (most in China (1), Canada (1), France (1)). By phase: Phase 1/2 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 11Countries
All recruiting trials (2)
-
E-islet 01 therapy for people with long-standing Type 1 diabetes and impaired hypoglycemia awareness
This trial will test whether E-islet 01, an allogeneic human islet cell therapy, is safe and helps reduce severe or unrecognized low blood sugars in people with Type 1 diabetes of more than five years’ duration.
-
Evaluating VX-880 for Type 1 Diabetes with Severe Hypoglycemia
This study is testing if a new treatment called VX-880 can help people with Type 1 diabetes who have trouble sensing low blood sugar and have had severe low blood sugar episodes.
Related topics
Quick answers
How many Impaired Hypoglycemic Awareness clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 11 countries. The most sites are in China (1 trial), Canada (1 trial), France (1 trial), Germany (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.